- Home
- SVRE vs CYCC Comparison
SVRE vs CYCC Comparison
Compare SVRE & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRE
- CYCC
- Stock Information
- Founded
- SVRE 2014
- CYCC 1992
- Country
- SVRE Israel
- CYCC United States
- Employees
- SVRE N/A
- CYCC N/A
- Industry
- SVRE
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- SVRE
- CYCC Health Care
- Exchange
- SVRE Nasdaq
- CYCC Nasdaq
- Market Cap
- SVRE 4.1M
- CYCC 3.6M
- IPO Year
- SVRE 2022
- CYCC N/A
- Fundamental
- Price
- SVRE $4.11
- CYCC $0.34
- Analyst Decision
- SVRE
- CYCC Strong Buy
- Analyst Count
- SVRE 0
- CYCC 1
- Target Price
- SVRE N/A
- CYCC $11.00
- AVG Volume (30 Days)
- SVRE 69.5K
- CYCC 404.4K
- Earning Date
- SVRE 03-24-2025
- CYCC 03-18-2025
- Dividend Yield
- SVRE N/A
- CYCC N/A
- EPS Growth
- SVRE N/A
- CYCC N/A
- EPS
- SVRE N/A
- CYCC N/A
- Revenue
- SVRE $458,952.00
- CYCC $74,000.00
- Revenue This Year
- SVRE N/A
- CYCC N/A
- Revenue Next Year
- SVRE $422.52
- CYCC $88.68
- P/E Ratio
- SVRE N/A
- CYCC N/A
- Revenue Growth
- SVRE N/A
- CYCC N/A
- 52 Week Low
- SVRE $3.84
- CYCC $0.30
- 52 Week High
- SVRE $359.95
- CYCC $4.00
- Technical
- Relative Strength Index (RSI)
- SVRE 26.43
- CYCC 46.57
- Support Level
- SVRE $5.07
- CYCC $0.32
- Resistance Level
- SVRE $7.33
- CYCC $0.38
- Average True Range (ATR)
- SVRE 1.11
- CYCC 0.02
- MACD
- SVRE 0.02
- CYCC 0.00
- Stochastic Oscillator
- SVRE 5.81
- CYCC 50.00
About SVRE SaverOne 2014 Ltd.
Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The Company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road, and pedestrians.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.